# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Raymond James analyst John Ransom upgrades GoodRx Holdings (NASDAQ:GDRX) from Market Perform to Outperform and announces $10...
TD Cowen analyst Charles Rhyee maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and raises the price target from $14 to $16.
GoodRX shares surged nearly 10% Wednesday afternoon following the announcement of a new direct contracting agreement with Kroge...
GoodRx's Q1 earnings: $0.08 EPS, sales hit $197.88 million, beating expectations fueled by prescription transactions and ph...